RP-G28 Product Platform

RP-G28 is a clinical-stage product candidate that has been derived from a platform technology called colonic adaptation. It has completed a Phase 2 trial aimed at showing its’ safety and efficacy along with supporting the mechanism of colonic adaptation. RP-G28 is also expected to have applicability to multiple types of gastrointestinal disorders.

RP-G28 may achieve long-term mitigation of symptoms associated with GI disorders.